The bitter side of epigenetics: variability and resistance to chemotherapy
File(s)
Accepted version
Author(s)
Hajji, Nabil
García-Domínguez, Daniel J
Hontecillas-Prieto, Lourdes
O'Neill, Kevin
de Álava, Enrique
Type
Journal Article
Abstract
One of the major obstacles to the development of effective new cancer treatments and the main factor for the increasing number of clinical trial failures appears to be the paucity of accurate, reproducible and robust drug resistance testing methods. Most research assessing the resistance of cancers to chemotherapy has concentrated on genetic-based molecular mechanisms, while the role of epigenetics in drug resistance has been generally overlooked. This is rather surprising given that an increasing body of evidence pointing to the fact that epigenetic mechanism alterations appear to play a pivotal role in cancer initiation, progression and development of chemoresistance. This resulted in a series of clinical trials involving epi-drug as single treatment or combined with cancer conventional drugs. In this review, we provided the main mechanisms by which the epigenetic regulators control the resistance to cancer drugs.
Date Issued
2021-03-01
Date Acceptance
2018-06-02
Citation
Epigenomics, 2021, 13 (5), pp.397-403
ISSN
1750-1911
Publisher
Future Medicine
Start Page
397
End Page
403
Journal / Book Title
Epigenomics
Volume
13
Issue
5
Copyright Statement
© 2018 Future Medicine Ltd
Sponsor
Brain Tumour Research Campaign
Barrow Foundation UK
Brain Tumour Research Campaign
Brain Tumour Research
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/29932342
Grant Number
n/a
N/A
N/A
Subjects
cancer epigenetics
epigenetic regulations
epigenetic therapies
Publication Status
Published
Coverage Spatial
England
Date Publish Online
2018-06-22